Larry Gold
Concepts (348)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Aptamers, Nucleotide | 10 | 2024 | 83 | 2.210 |
Why?
| | RNA | 24 | 2020 | 921 | 1.780 |
Why?
| | SELEX Aptamer Technique | 7 | 2016 | 15 | 1.320 |
Why?
| | Proteomics | 12 | 2024 | 1111 | 1.240 |
Why?
| | T-Phages | 15 | 1991 | 18 | 1.140 |
Why?
| | Nucleic Acid Conformation | 33 | 2000 | 728 | 1.050 |
Why?
| | RNA, Catalytic | 4 | 2020 | 187 | 1.050 |
Why?
| | Base Sequence | 53 | 2003 | 2181 | 1.040 |
Why?
| | Molecular Sequence Data | 53 | 2012 | 2900 | 0.970 |
Why?
| | Escherichia coli | 23 | 1997 | 815 | 0.960 |
Why?
| | Proteome | 8 | 2024 | 472 | 0.870 |
Why?
| | Oligoribonucleotides | 10 | 1997 | 52 | 0.770 |
Why?
| | Viral Proteins | 14 | 1997 | 342 | 0.750 |
Why?
| | DNA, Single-Stranded | 7 | 2003 | 118 | 0.710 |
Why?
| | Ligands | 22 | 2016 | 664 | 0.690 |
Why?
| | Proteins | 10 | 2023 | 1009 | 0.690 |
Why?
| | Ribonucleotides | 1 | 2020 | 26 | 0.660 |
Why?
| | RNA, Messenger | 16 | 2017 | 2833 | 0.650 |
Why?
| | Biomarkers | 9 | 2015 | 4149 | 0.650 |
Why?
| | Ribosomes | 12 | 1995 | 186 | 0.650 |
Why?
| | Oligonucleotides | 5 | 2023 | 148 | 0.620 |
Why?
| | Oligodeoxyribonucleotides | 8 | 2003 | 143 | 0.620 |
Why?
| | Reverse Transcriptase Inhibitors | 6 | 1996 | 84 | 0.600 |
Why?
| | Blood Proteins | 4 | 2017 | 252 | 0.580 |
Why?
| | Genes, Viral | 11 | 1995 | 88 | 0.530 |
Why?
| | Peptide Chain Initiation, Translational | 6 | 1995 | 44 | 0.500 |
Why?
| | Protein Biosynthesis | 10 | 1997 | 433 | 0.480 |
Why?
| | Binding Sites | 23 | 2000 | 1303 | 0.480 |
Why?
| | RNA, Viral | 10 | 2000 | 656 | 0.450 |
Why?
| | HIV-1 | 8 | 1996 | 864 | 0.440 |
Why?
| | Muscular Dystrophy, Duchenne | 1 | 2015 | 89 | 0.440 |
Why?
| | Q beta Replicase | 4 | 1996 | 4 | 0.410 |
Why?
| | RNA, Ribosomal | 1 | 2014 | 168 | 0.410 |
Why?
| | Diagnosis | 2 | 2013 | 13 | 0.390 |
Why?
| | Capsid | 3 | 2000 | 93 | 0.390 |
Why?
| | DNA | 4 | 2011 | 1459 | 0.380 |
Why?
| | Bacteriophage T4 | 4 | 1997 | 15 | 0.380 |
Why?
| | Protein Binding | 14 | 2023 | 2224 | 0.350 |
Why?
| | Kinetics | 14 | 2010 | 1670 | 0.330 |
Why?
| | Polymerase Chain Reaction | 15 | 2000 | 1062 | 0.330 |
Why?
| | Gene Products, rev | 2 | 2002 | 6 | 0.320 |
Why?
| | HIV Reverse Transcriptase | 5 | 1996 | 31 | 0.320 |
Why?
| | DNA-Directed DNA Polymerase | 3 | 1997 | 44 | 0.300 |
Why?
| | History, 20th Century | 3 | 2015 | 325 | 0.290 |
Why?
| | Capsid Proteins | 2 | 2000 | 94 | 0.290 |
Why?
| | Information Systems | 3 | 1998 | 61 | 0.290 |
Why?
| | Evolution, Molecular | 4 | 2020 | 493 | 0.280 |
Why?
| | RNA, Bacterial | 4 | 2000 | 190 | 0.280 |
Why?
| | Bacterial Proteins | 4 | 1996 | 879 | 0.280 |
Why?
| | Biological Evolution | 5 | 2014 | 474 | 0.270 |
Why?
| | RNA-Binding Proteins | 4 | 2000 | 422 | 0.260 |
Why?
| | RNA, Transfer | 4 | 1991 | 138 | 0.250 |
Why?
| | Directed Molecular Evolution | 2 | 1996 | 21 | 0.250 |
Why?
| | RNA Processing, Post-Transcriptional | 4 | 1996 | 92 | 0.250 |
Why?
| | DNA Primers | 10 | 2012 | 515 | 0.250 |
Why?
| | DNA-Binding Proteins | 5 | 1993 | 1502 | 0.240 |
Why?
| | Bacteriophages | 2 | 2000 | 98 | 0.240 |
Why?
| | RNA-Directed DNA Polymerase | 5 | 1996 | 34 | 0.240 |
Why?
| | Protein Array Analysis | 3 | 2014 | 57 | 0.230 |
Why?
| | Cloning, Molecular | 11 | 1998 | 534 | 0.230 |
Why?
| | Clinical Laboratory Techniques | 2 | 2003 | 97 | 0.230 |
Why?
| | Gene Library | 2 | 2010 | 118 | 0.230 |
Why?
| | Tenascin | 1 | 2003 | 15 | 0.220 |
Why?
| | Oligonucleotide Array Sequence Analysis | 2 | 2010 | 767 | 0.210 |
Why?
| | Templates, Genetic | 6 | 2003 | 63 | 0.210 |
Why?
| | Amino Acid Sequence | 9 | 2003 | 2139 | 0.200 |
Why?
| | Peptide Initiation Factors | 3 | 1993 | 16 | 0.200 |
Why?
| | DNA, Bacterial | 5 | 1997 | 337 | 0.190 |
Why?
| | Biomarkers, Tumor | 3 | 2012 | 1276 | 0.190 |
Why?
| | Codon | 7 | 1994 | 89 | 0.190 |
Why?
| | Protein Interaction Mapping | 1 | 2002 | 109 | 0.180 |
Why?
| | Plasmids | 6 | 1992 | 363 | 0.180 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2002 | 184 | 0.180 |
Why?
| | Reproducibility of Results | 6 | 2024 | 3284 | 0.180 |
Why?
| | Bacteriophage lambda | 3 | 1992 | 88 | 0.180 |
Why?
| | Genomic Library | 2 | 2000 | 18 | 0.180 |
Why?
| | Antibodies | 3 | 2014 | 410 | 0.170 |
Why?
| | Combinatorial Chemistry Techniques | 1 | 2000 | 17 | 0.170 |
Why?
| | Aptamers, Peptide | 2 | 2011 | 3 | 0.160 |
Why?
| | Substrate Specificity | 6 | 2000 | 372 | 0.160 |
Why?
| | Genome, Bacterial | 1 | 2000 | 142 | 0.160 |
Why?
| | Neoplasm Proteins | 1 | 2003 | 434 | 0.160 |
Why?
| | Gene Expression Regulation | 6 | 2002 | 2607 | 0.160 |
Why?
| | Structure-Activity Relationship | 7 | 2002 | 570 | 0.150 |
Why?
| | Nucleic Acids | 2 | 2011 | 71 | 0.150 |
Why?
| | Humans | 30 | 2024 | 137585 | 0.150 |
Why?
| | Recombinant Proteins | 7 | 2014 | 1353 | 0.140 |
Why?
| | Computer Simulation | 3 | 1998 | 978 | 0.140 |
Why?
| | Mass Spectrometry | 4 | 2010 | 739 | 0.140 |
Why?
| | Chloramphenicol | 1 | 1997 | 9 | 0.140 |
Why?
| | Peptidyl Transferases | 1 | 1997 | 8 | 0.140 |
Why?
| | Antiviral Agents | 2 | 1995 | 744 | 0.140 |
Why?
| | Erythrocyte Membrane | 1 | 1998 | 55 | 0.140 |
Why?
| | Ribosomal Proteins | 2 | 1995 | 93 | 0.140 |
Why?
| | S-Adenosylmethionine | 1 | 1997 | 54 | 0.130 |
Why?
| | DNA, Viral | 4 | 1993 | 364 | 0.130 |
Why?
| | Binding, Competitive | 5 | 1996 | 202 | 0.130 |
Why?
| | Guanosine Monophosphate | 1 | 1996 | 8 | 0.130 |
Why?
| | Gene Products, gag | 1 | 1996 | 36 | 0.130 |
Why?
| | Bradykinin | 1 | 1996 | 46 | 0.130 |
Why?
| | Endpoint Determination | 1 | 2017 | 77 | 0.130 |
Why?
| | Molecular Biology | 1 | 1997 | 59 | 0.130 |
Why?
| | Models, Molecular | 4 | 2012 | 1570 | 0.130 |
Why?
| | Nucleic Acid Hybridization | 2 | 2010 | 190 | 0.130 |
Why?
| | Repressor Proteins | 3 | 1996 | 427 | 0.130 |
Why?
| | DNA Replication | 3 | 1993 | 238 | 0.120 |
Why?
| | DNA Nucleotidyltransferases | 1 | 1995 | 11 | 0.120 |
Why?
| | Base Composition | 4 | 1996 | 78 | 0.120 |
Why?
| | RNA, Antisense | 2 | 1992 | 17 | 0.120 |
Why?
| | Adenosine | 1 | 1997 | 225 | 0.120 |
Why?
| | Endoribonucleases | 1 | 1996 | 81 | 0.120 |
Why?
| | Substance P | 1 | 1995 | 36 | 0.120 |
Why?
| | Nerve Growth Factors | 1 | 1995 | 79 | 0.120 |
Why?
| | Eye Diseases | 1 | 2016 | 87 | 0.120 |
Why?
| | Ribonucleases | 1 | 1994 | 55 | 0.110 |
Why?
| | Ophthalmology | 1 | 2016 | 86 | 0.110 |
Why?
| | Consensus Sequence | 5 | 2000 | 73 | 0.110 |
Why?
| | Transcription, Genetic | 5 | 2000 | 1457 | 0.110 |
Why?
| | Models, Theoretical | 1 | 1998 | 578 | 0.110 |
Why?
| | Origin of Life | 1 | 2014 | 8 | 0.110 |
Why?
| | RNA, Transfer, Amino Acid-Specific | 1 | 1994 | 4 | 0.110 |
Why?
| | Selenocysteine | 1 | 1994 | 4 | 0.110 |
Why?
| | RNA, Transfer, Amino Acyl | 1 | 1994 | 9 | 0.110 |
Why?
| | Hydrolysis | 4 | 1997 | 177 | 0.110 |
Why?
| | Peptide Elongation Factors | 1 | 1994 | 15 | 0.110 |
Why?
| | Enzyme Inhibitors | 1 | 1997 | 840 | 0.110 |
Why?
| | Escherichia coli Proteins | 1 | 1996 | 200 | 0.110 |
Why?
| | Genetic Techniques | 2 | 2010 | 64 | 0.110 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 3 | 2010 | 852 | 0.100 |
Why?
| | Genetic Vectors | 2 | 1992 | 319 | 0.100 |
Why?
| | Catalysis | 3 | 2002 | 307 | 0.100 |
Why?
| | Operator Regions, Genetic | 2 | 1990 | 7 | 0.100 |
Why?
| | Sensitivity and Specificity | 4 | 2010 | 1946 | 0.100 |
Why?
| | History, 21st Century | 1 | 2014 | 213 | 0.100 |
Why?
| | Models, Genetic | 3 | 1991 | 600 | 0.100 |
Why?
| | Proto-Oncogene Proteins c-sis | 1 | 2012 | 39 | 0.100 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 2 | 2012 | 1081 | 0.100 |
Why?
| | Drug Therapy | 1 | 2013 | 85 | 0.100 |
Why?
| | Genes, pX | 1 | 1992 | 2 | 0.100 |
Why?
| | Deoxyribonuclease EcoRI | 1 | 1992 | 4 | 0.100 |
Why?
| | Affinity Labels | 2 | 2014 | 26 | 0.090 |
Why?
| | Body Fluids | 1 | 2012 | 66 | 0.090 |
Why?
| | Case-Control Studies | 3 | 2015 | 3556 | 0.090 |
Why?
| | Hydrophobic and Hydrophilic Interactions | 1 | 2012 | 187 | 0.090 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 4 | 1993 | 345 | 0.090 |
Why?
| | Diagnostic Techniques and Procedures | 1 | 2011 | 21 | 0.090 |
Why?
| | Sequence Homology, Nucleic Acid | 4 | 1995 | 155 | 0.090 |
Why?
| | Mutation | 7 | 1995 | 3958 | 0.090 |
Why?
| | Ribonucleotide Reductases | 1 | 1991 | 31 | 0.090 |
Why?
| | DNA Transposable Elements | 1 | 1992 | 121 | 0.090 |
Why?
| | RNA, Ribosomal, 16S | 1 | 1993 | 549 | 0.090 |
Why?
| | Biological Assay | 1 | 2011 | 124 | 0.090 |
Why?
| | Chromosome Deletion | 1 | 1991 | 115 | 0.090 |
Why?
| | Transcription Factors | 2 | 1989 | 1719 | 0.080 |
Why?
| | Introns | 1 | 1991 | 258 | 0.080 |
Why?
| | Anti-HIV Agents | 1 | 1996 | 778 | 0.080 |
Why?
| | Genes, Regulator | 1 | 1989 | 37 | 0.080 |
Why?
| | Animals | 7 | 2014 | 36940 | 0.080 |
Why?
| | Promoter Regions, Genetic | 3 | 1991 | 1250 | 0.080 |
Why?
| | Micrococcal Nuclease | 1 | 1989 | 26 | 0.080 |
Why?
| | Neoplasms | 2 | 2012 | 2671 | 0.080 |
Why?
| | Databases, Protein | 1 | 2009 | 85 | 0.080 |
Why?
| | Exodeoxyribonucleases | 1 | 1988 | 22 | 0.070 |
Why?
| | Genetic Predisposition to Disease | 1 | 2017 | 2426 | 0.070 |
Why?
| | Metalloproteins | 1 | 1987 | 6 | 0.070 |
Why?
| | Lung Neoplasms | 2 | 2012 | 2526 | 0.070 |
Why?
| | Trans-Activators | 1 | 1990 | 398 | 0.070 |
Why?
| | Avian Myeloblastosis Virus | 3 | 1996 | 4 | 0.070 |
Why?
| | Computational Biology | 2 | 2003 | 644 | 0.070 |
Why?
| | Cohort Studies | 2 | 2015 | 5742 | 0.070 |
Why?
| | Societies | 1 | 2007 | 39 | 0.070 |
Why?
| | Glomerular Filtration Rate | 1 | 2010 | 746 | 0.070 |
Why?
| | Genes, Bacterial | 2 | 2000 | 164 | 0.060 |
Why?
| | Hydrogen-Ion Concentration | 3 | 2004 | 560 | 0.060 |
Why?
| | Oligonucleotide Probes | 3 | 1991 | 51 | 0.060 |
Why?
| | Sequence Analysis | 2 | 1996 | 36 | 0.060 |
Why?
| | Evidence-Based Medicine | 1 | 2010 | 740 | 0.060 |
Why?
| | Peptide Fragments | 2 | 2003 | 706 | 0.060 |
Why?
| | Conserved Sequence | 2 | 1997 | 239 | 0.060 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2012 | 1396 | 0.060 |
Why?
| | Early Detection of Cancer | 1 | 2010 | 447 | 0.060 |
Why?
| | Mathematics | 2 | 1998 | 103 | 0.060 |
Why?
| | Kidney Failure, Chronic | 1 | 2010 | 570 | 0.060 |
Why?
| | Membrane Proteins | 2 | 2003 | 1164 | 0.060 |
Why?
| | Zinc | 1 | 1987 | 297 | 0.060 |
Why?
| | Macromolecular Substances | 2 | 1996 | 229 | 0.050 |
Why?
| | Models, Biological | 1 | 1991 | 1783 | 0.050 |
Why?
| | DNA, Fungal | 2 | 1997 | 80 | 0.050 |
Why?
| | RNA, Transfer, Met | 2 | 1994 | 7 | 0.050 |
Why?
| | Molecular Structure | 2 | 2012 | 489 | 0.050 |
Why?
| | Hydrogen Bonding | 2 | 1994 | 163 | 0.050 |
Why?
| | beta-Galactosidase | 3 | 1994 | 78 | 0.050 |
Why?
| | Restriction Mapping | 2 | 1995 | 77 | 0.050 |
Why?
| | Selection, Genetic | 2 | 1998 | 273 | 0.050 |
Why?
| | Ultraviolet Rays | 2 | 1996 | 396 | 0.050 |
Why?
| | Spin Labels | 1 | 2023 | 48 | 0.050 |
Why?
| | Human Genome Project | 1 | 2003 | 15 | 0.050 |
Why?
| | United States | 2 | 2015 | 14841 | 0.050 |
Why?
| | Electron Spin Resonance Spectroscopy | 1 | 2023 | 95 | 0.050 |
Why?
| | Drug Design | 2 | 1995 | 167 | 0.050 |
Why?
| | Isomerism | 2 | 1992 | 56 | 0.050 |
Why?
| | Education, Continuing | 1 | 2003 | 39 | 0.050 |
Why?
| | Gene Expression | 3 | 1992 | 1502 | 0.050 |
Why?
| | Adenosine Triphosphate | 2 | 1997 | 491 | 0.050 |
Why?
| | Tumor Cells, Cultured | 1 | 2003 | 955 | 0.050 |
Why?
| | Complement System Proteins | 2 | 2017 | 327 | 0.050 |
Why?
| | Chromatography, Liquid | 1 | 2003 | 433 | 0.050 |
Why?
| | Molecular Diagnostic Techniques | 2 | 2014 | 105 | 0.050 |
Why?
| | Sequence Analysis, DNA | 2 | 2012 | 812 | 0.040 |
Why?
| | Cross-Linking Reagents | 2 | 2004 | 217 | 0.040 |
Why?
| | RNA, Fungal | 2 | 1991 | 72 | 0.040 |
Why?
| | Prokaryotic Initiation Factor-3 | 2 | 1990 | 7 | 0.040 |
Why?
| | Genome | 1 | 2002 | 300 | 0.040 |
Why?
| | Child, Preschool | 1 | 2015 | 11074 | 0.040 |
Why?
| | In Vitro Techniques | 2 | 1995 | 1092 | 0.040 |
Why?
| | Artifacts | 1 | 2000 | 129 | 0.040 |
Why?
| | Glioblastoma | 1 | 2003 | 345 | 0.040 |
Why?
| | Saccharomyces cerevisiae | 2 | 1997 | 557 | 0.040 |
Why?
| | Machine Learning | 1 | 2024 | 493 | 0.040 |
Why?
| | Genetic Variation | 2 | 2017 | 991 | 0.040 |
Why?
| | Young Adult | 1 | 2015 | 13209 | 0.040 |
Why?
| | RNA, Ribosomal, 23S | 1 | 1997 | 14 | 0.040 |
Why?
| | DNA Mutational Analysis | 2 | 1990 | 399 | 0.040 |
Why?
| | Male | 3 | 2015 | 67762 | 0.030 |
Why?
| | International Cooperation | 2 | 2009 | 198 | 0.030 |
Why?
| | Genomics | 1 | 2003 | 795 | 0.030 |
Why?
| | gag Gene Products, Human Immunodeficiency Virus | 1 | 1996 | 11 | 0.030 |
Why?
| | Peptide Elongation Factor Tu | 1 | 1996 | 5 | 0.030 |
Why?
| | Uridine Triphosphate | 1 | 1996 | 10 | 0.030 |
Why?
| | Butanones | 1 | 1996 | 3 | 0.030 |
Why?
| | Alkylation | 1 | 1996 | 26 | 0.030 |
Why?
| | Replicon | 1 | 1996 | 14 | 0.030 |
Why?
| | Thionucleotides | 1 | 1996 | 35 | 0.030 |
Why?
| | Molecular Sequence Annotation | 1 | 2017 | 99 | 0.030 |
Why?
| | NAD | 1 | 1997 | 77 | 0.030 |
Why?
| | Heme | 1 | 2017 | 78 | 0.030 |
Why?
| | Metals | 1 | 1997 | 136 | 0.030 |
Why?
| | Gene Dosage | 1 | 1997 | 140 | 0.030 |
Why?
| | Sulfur | 1 | 1996 | 58 | 0.030 |
Why?
| | rev Gene Products, Human Immunodeficiency Virus | 1 | 1995 | 6 | 0.030 |
Why?
| | Single-Strand Specific DNA and RNA Endonucleases | 1 | 1995 | 10 | 0.030 |
Why?
| | Immunodeficiency Virus, Feline | 1 | 1996 | 34 | 0.030 |
Why?
| | Neoplasm Metastasis | 2 | 2012 | 658 | 0.030 |
Why?
| | Adolescent | 1 | 2015 | 21513 | 0.030 |
Why?
| | Buffers | 1 | 1995 | 56 | 0.030 |
Why?
| | Aldehydes | 1 | 1996 | 145 | 0.030 |
Why?
| | Mammary Tumor Virus, Mouse | 1 | 1995 | 44 | 0.030 |
Why?
| | Viral Structural Proteins | 1 | 1995 | 13 | 0.030 |
Why?
| | Pharmacogenetics | 1 | 2017 | 180 | 0.030 |
Why?
| | Sepharose | 1 | 1995 | 34 | 0.030 |
Why?
| | Viruses | 1 | 1996 | 113 | 0.030 |
Why?
| | RNA Splicing | 1 | 2017 | 269 | 0.030 |
Why?
| | Child | 1 | 2015 | 21935 | 0.030 |
Why?
| | Virus Integration | 1 | 1995 | 71 | 0.030 |
Why?
| | Glycoproteins | 1 | 2017 | 342 | 0.030 |
Why?
| | Arginine | 1 | 1996 | 271 | 0.030 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 1997 | 611 | 0.030 |
Why?
| | Sodium Chloride | 1 | 1995 | 142 | 0.030 |
Why?
| | Enzyme Induction | 1 | 1994 | 90 | 0.030 |
Why?
| | Ribonuclease H | 1 | 1994 | 12 | 0.030 |
Why?
| | Leukemia Virus, Murine | 1 | 1994 | 18 | 0.030 |
Why?
| | Quantitative Trait Loci | 1 | 2017 | 380 | 0.030 |
Why?
| | Gene Regulatory Networks | 1 | 2017 | 305 | 0.030 |
Why?
| | Genome, Human | 1 | 2017 | 425 | 0.030 |
Why?
| | Integrases | 1 | 1995 | 120 | 0.030 |
Why?
| | Aged | 2 | 2012 | 23961 | 0.030 |
Why?
| | Selenoproteins | 1 | 1994 | 7 | 0.030 |
Why?
| | Protein Processing, Post-Translational | 1 | 2017 | 465 | 0.030 |
Why?
| | Peptide Chain Elongation, Translational | 1 | 1994 | 18 | 0.030 |
Why?
| | RNA, Transfer, Phe | 1 | 1993 | 9 | 0.030 |
Why?
| | DNA, Complementary | 1 | 1994 | 272 | 0.030 |
Why?
| | Models, Structural | 1 | 1993 | 40 | 0.030 |
Why?
| | Alleles | 1 | 2017 | 891 | 0.030 |
Why?
| | Drug Delivery Systems | 1 | 2017 | 365 | 0.030 |
Why?
| | Rho Factor | 1 | 1993 | 4 | 0.030 |
Why?
| | Electrophoresis | 1 | 1992 | 32 | 0.030 |
Why?
| | Chromatography, Affinity | 1 | 1993 | 88 | 0.030 |
Why?
| | Transition Temperature | 1 | 2012 | 26 | 0.020 |
Why?
| | Software | 1 | 1998 | 665 | 0.020 |
Why?
| | Mutagenesis, Site-Directed | 1 | 1993 | 375 | 0.020 |
Why?
| | Allosteric Regulation | 1 | 1992 | 97 | 0.020 |
Why?
| | RNA, Small Untranslated | 1 | 2012 | 16 | 0.020 |
Why?
| | Middle Aged | 2 | 2012 | 33479 | 0.020 |
Why?
| | Lac Operon | 1 | 1992 | 44 | 0.020 |
Why?
| | Amino Acid Motifs | 1 | 2012 | 225 | 0.020 |
Why?
| | Adult | 1 | 2015 | 37929 | 0.020 |
Why?
| | Complement Inactivating Agents | 1 | 2013 | 63 | 0.020 |
Why?
| | Titrimetry | 1 | 2011 | 12 | 0.020 |
Why?
| | Random Allocation | 1 | 1992 | 353 | 0.020 |
Why?
| | Limit of Detection | 1 | 2011 | 85 | 0.020 |
Why?
| | Ion Channels | 1 | 1992 | 133 | 0.020 |
Why?
| | Automation | 1 | 2011 | 95 | 0.020 |
Why?
| | Alkaline Phosphatase | 1 | 1992 | 148 | 0.020 |
Why?
| | Nanotechnology | 1 | 2012 | 125 | 0.020 |
Why?
| | Anticodon | 1 | 1991 | 24 | 0.020 |
Why?
| | Sequence Analysis, RNA | 1 | 1994 | 452 | 0.020 |
Why?
| | Crystallography, X-Ray | 1 | 2012 | 476 | 0.020 |
Why?
| | Triticum | 1 | 1990 | 17 | 0.020 |
Why?
| | Endodeoxyribonucleases | 1 | 1991 | 72 | 0.020 |
Why?
| | Sequence Alignment | 1 | 1991 | 343 | 0.020 |
Why?
| | Neoplasm Invasiveness | 1 | 2012 | 510 | 0.020 |
Why?
| | Recombination, Genetic | 1 | 1991 | 204 | 0.020 |
Why?
| | Neovascularization, Pathologic | 1 | 2012 | 301 | 0.020 |
Why?
| | Gene Expression Regulation, Viral | 1 | 1990 | 95 | 0.020 |
Why?
| | Germany | 1 | 1990 | 121 | 0.020 |
Why?
| | Placenta | 1 | 1997 | 750 | 0.020 |
Why?
| | Data Interpretation, Statistical | 1 | 1992 | 363 | 0.020 |
Why?
| | Genome-Wide Association Study | 1 | 2017 | 1431 | 0.020 |
Why?
| | Tetrahydrofolate Dehydrogenase | 1 | 1989 | 23 | 0.020 |
Why?
| | Databases, Factual | 1 | 1995 | 1357 | 0.020 |
Why?
| | Nervous System Diseases | 1 | 2012 | 266 | 0.020 |
Why?
| | Database Management Systems | 1 | 2009 | 51 | 0.020 |
Why?
| | Regulatory Sequences, Nucleic Acid | 1 | 1989 | 91 | 0.020 |
Why?
| | Recombinant Fusion Proteins | 1 | 1992 | 665 | 0.020 |
Why?
| | Exodeoxyribonuclease V | 1 | 1988 | 6 | 0.020 |
Why?
| | Open Reading Frames | 1 | 1989 | 123 | 0.020 |
Why?
| | Genes | 1 | 1988 | 230 | 0.020 |
Why?
| | Phosphorylation | 1 | 2012 | 1759 | 0.020 |
Why?
| | Genetic Complementation Test | 1 | 1987 | 67 | 0.020 |
Why?
| | RNA Caps | 1 | 1988 | 35 | 0.020 |
Why?
| | Terminology as Topic | 1 | 2009 | 216 | 0.020 |
Why?
| | Gene Conversion | 1 | 1987 | 7 | 0.020 |
Why?
| | Models, Statistical | 1 | 2010 | 669 | 0.020 |
Why?
| | Female | 2 | 2012 | 73304 | 0.020 |
Why?
| | Europe | 1 | 2007 | 414 | 0.020 |
Why?
| | Virus Replication | 1 | 1987 | 483 | 0.010 |
Why?
| | Endostatins | 1 | 2004 | 10 | 0.010 |
Why?
| | Interleukin-16 | 1 | 2004 | 6 | 0.010 |
Why?
| | Lod Score | 1 | 2004 | 67 | 0.010 |
Why?
| | Tissue Inhibitor of Metalloproteinase-1 | 1 | 2004 | 26 | 0.010 |
Why?
| | Antibodies, Monoclonal | 1 | 1991 | 1430 | 0.010 |
Why?
| | Fibroblast Growth Factor 2 | 1 | 2004 | 87 | 0.010 |
Why?
| | Carrier Proteins | 1 | 1987 | 771 | 0.010 |
Why?
| | Algorithms | 1 | 2010 | 1704 | 0.010 |
Why?
| | Apoptosis | 1 | 2012 | 2553 | 0.010 |
Why?
| | Smoking | 1 | 2010 | 1627 | 0.010 |
Why?
| | Autoantibodies | 1 | 2010 | 1496 | 0.010 |
Why?
| | Risk Factors | 1 | 2017 | 10388 | 0.010 |
Why?
| | Colonic Neoplasms | 1 | 2004 | 258 | 0.010 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2004 | 545 | 0.010 |
Why?
| | Light | 1 | 2004 | 381 | 0.010 |
Why?
| | Inflammation | 1 | 2012 | 2837 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2004 | 2057 | 0.010 |
Why?
| | Moloney murine leukemia virus | 1 | 1996 | 13 | 0.010 |
Why?
| | Zidovudine | 1 | 1996 | 78 | 0.010 |
Why?
| | Repetitive Sequences, Nucleic Acid | 1 | 1996 | 113 | 0.010 |
Why?
| | Cats | 1 | 1996 | 210 | 0.010 |
Why?
| | Virion | 1 | 1996 | 93 | 0.010 |
Why?
|
|
Gold's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|